July 8, 2024

NeoLight Announces Exclusive USA Partnership with ANT Neuro for nëo™ CFM System

Revolutionary Neonatal Brain Monitoring System Now Available to U.S. Hospitals and NICUs through NeoLight
Geometric shape

Scottsdale, Arizona, July 08, 2024– NeoLight, a leading innovator in neonatal care, is proud to announce that it has entered into an exclusive distribution agreement with ANT Neuro to bring the state-of-the-art nëo CFM (Cerebral Function Monitor) to neonatal intensive care units (NICUs) across the United States. This agreement allows NeoLight to be the authorized distributor of the nëo CFM system, enhancing the company’s portfolio of neonatal care solutions.

nëo CFM leverages ClearWave™ aEEG to provide clear and reliable data. This allows clinicians to assess key aspects of brain function, including background activity and cyclicity. Utilizing nëo BrainCare™ Suite, nëo CFM provides advanced monitoring and superior clarity for exceptional neonatal care.

“We are thrilled to partner with ANT Neuro to distribute the nëo CFM in the U.S. market,” said Vivek Kopparthi, Co-founder and CEO of NeoLight. “This innovative monitoring system aligns perfectly with our mission to advance neonatal care and provide healthcare professionals with the tools they need to improve outcomes for the most vulnerable patients. The nëo CFM represents a significant advancement in neonatal brain monitoring, and we are excited to bring this life-saving technology to NICUs in the USA.”

Bernd Tebje, Director of International Sales at ANT Neuro, shared his enthusiasm about the partnership, stating, “Collaborating with NeoLight allows us to bring the groundbreaking nëo CFM system to a wider audience within the U.S. healthcare system. We believe that the integration of our cutting-edge neurotechnology with NeoLight’s commitment to neonatal care will set a new standard for brain monitoring in NICUs. This partnership is a major step forward in our mission to enhance patient care and support clinicians with reliable and advanced diagnostic tools.”

ANT Neuro, renowned for its expertise in neurotechnology and brain monitoring solutions, has developed the nëo CFM to meet the highest standards of quality and performance. This collaboration with NeoLight underscores ANT Neuro’s commitment to expanding the accessibility of its cutting-edge products in the U.S. market.

As NeoLight continues to innovate and expand its product offerings, the addition of the nëo CFM marks a significant milestone in the company’s journey to transform neonatal care through advanced technology and dedicated service.

NeoLight is a medical device company that develops empathy driven, best-in-class technologies for treating preventable conditions in the newborn care market. Empathy driven solutions are a framework that has the doctor-nurse-mother-infant ecosystem at the center. It fosters the emotional connection that happens, thereby providing not just treatment but also providing care. Driving neonatal care beyond the traditional hospital setting, NeoLight is also creating a robust home market to treat neonatal conditions in the home. To learn more, visit www.theneolight.com and follow us on Twitter and LinkedIn.